Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer

Fig. 2

a. 5-year disease-free survival (DFS) in patients with ypN0, 73.9% vs ypN+, 43.6%; p = 0.031. b. 5-year disease-specific survival (DSS) in patients with ypN0, 78% vs ypN+, 48.1%; p = 0.008. c. 5-year disease-free survival (DFS) in patients with MDACC Residual Cancer Burden Index Class 0, 88.9% vs MDACC Residual Cancer Burden Index Class I-III, 49.3%; p = 0.049. d. 5-year disease-free survival (DSS) in patients with MDACC Residual Cancer Burden Index Class 0, 88.9% vs MDACC Residual Cancer Burden Index Class I-III, 53%; p = 0.041

Back to article page
\